Posted by eYuppie > 2020-12-23 10:04 | Report Abuse

Noted with thanks abangloon666

Posted by lee9fold > 2020-12-23 11:36 |

Post removed.Why?

Posted by eYuppie > 2020-12-23 12:00 | Report Abuse

Sad to see that the current situation is so unclear to the stock traders because the govt does not announce how the vaccine that the govt dealt directly will going to be distributed, making everyone guessing. The PN govt seems keeping people under suspend. Why???

Posted by DrMichael > 2020-12-23 12:11 | Report Abuse

People tends to over-weight the term "Agreement" as in Tenancy Agreement, SnP Agreement, Loan Agreement or Deed of Debenture Agreement. They over-emphasis what they want to divert the attention by shouting loudly.

The "manufacturing, commercialisation and distribution agreement" is just that. It's not a "SOLE DISTRIBUTORSHIP" OR EXCLUSIVE DISTRIBUTOR" How would the start up and capital employed in such a venture be feasible and viable in the long run, with the small population of Malaysia at only 31 million?

Please see the News release CAREFULLY.....read again slowly...https://www.theedgemarkets.com/article/solution-group-subsidiary-signs-agreement-cansino-distribute-novel-coronavirus-vaccine

Albeit, on even playing fields, and that most of the Chinese Vaccines have completely CTIL and with only very thin documentations of such Trial, be given the benefits of the doubt, and viola, approved by one and all, even NPRA and allowed importations.....BUT....Malaysian Govt is providing, vaccinating, control and monitoring for FREE..FREE..FREE

AND THE PLC WISHES TO SELL INTO THE MARKET?

A play is just a play, no matter which angle you look at it.

Posted by DrMichael > 2020-12-23 12:15 | Report Abuse

The Govt has said it many times and in Pressers, "NO MIDDLEMAN" and if that still doesn't tell you that they only intend to bring in the Vaccines directly from the Pharmaceuticals giants, I don't know how to explain it anymore clearer.

Posted by DrMichael > 2020-12-23 12:20 |

Post removed.Why?

Posted by DrMichael > 2020-12-23 12:28 | Report Abuse

eYuppie, would suggest you scroll back to page 200 and read till present, some of the views and opinions shared. As mentioned we do not advocate or solicitous in sharing our views. Please feel free to contradict, but without profanities and humiliations. We do not pretend to be experts but to evaluate logically and realistically. Thank you.

Posted by DrMichael > 2020-12-23 12:47 | Report Abuse

Pertaining to the so-called Sole Distributorship, the chinese culture of doing business is an "open door". Whoever walks in with suitcases of green can be a customer. BUT to be granted the "Sole Distributorship", unless you have bought controlling stakes or they still owe you a living or you are their grandfather, they will not give a second glance or pass ownership of their products, especially at a freshly minted company.

Posted by LOOK009 > 2020-12-23 15:46 | Report Abuse

The most failed counter will not rebound.

Posted by apaimiggol > 2020-12-23 16:37 | Report Abuse

Govt in talks to secure more vaccines from Russia, Pfizer, says Khairy
Rozanna Latiff & Liz Lee
/
Reuters

December 23, 2020 15:47 pm +08
Govt in talks to secure more vaccines from Russia, Pfizer, says Khairy
-A
+A

KUALA LUMPUR (Dec 23): Malaysia is in talks to buy 6.4 million doses of Russia's Sputnik V Covid-19 vaccine and wants to increase its purchases from US drugmaker Pfizer-BioNTech as the country looks to beef up its arsenal against the pandemic.

The Southeast Asian nation is spending about US$500 million to buy enough vaccines to inoculate 26.5 million people or 82.8% of its people.

It has already bought vaccines from Pfizer and Britain's AstraZeneca and expects to secure more from Chinese and Russian manufacturers, as well as from its participation in the global COVAX facility, backed by the World Health Organization (WHO).
Advertisement

The government had increased its vaccine supply targets to take into account risks that some vaccines may not be approved by regulators or if manufacturers failed to deliver, Science, Technology and Innovation Minister Khairy Jamaluddin told reporters.

"We want to have a little bit more of a buffer," he said.

In addition to the talks with Russia's Gamaleya Institute, the developer of the Sputnik V Vaccine, Malaysia is also in discussions with Chinese manufacturers Sinovac Biotech Ltd and CanSino Biologics to purchase their vaccines.

The deals with the Chinese and Russian manufacturers will include cooperation with Malaysian companies to carry out fill-and-finish work, Khairy said.

Malaysia has also secured 6.4 million doses of AstraZeneca's vaccine through COVAX, doubling the amount it had already agreed to purchase from the drugmaker.

The government is also in negotiations with Pfizer on an option to increase its purchase of vaccines to cover another 20% of its population, Khairy added.

Malaysia has purchased 12.8 million doses of the Pfizer vaccine so far, with the first shipment expected to arrive in February.

Posted by huat8787 > 2020-12-23 16:39 | Report Abuse

epf keep sapu..good sign?

Posted by apaimiggol > 2020-12-23 16:39 | Report Abuse

"The deals with the Chinese and Russian manufacturers will include cooperation with Malaysian companies to carry out fill-and-finish work, Khairy said." meaning that DPHARMA will have chance to get projects on fill-and-finish works as they have the expertise and experiences as well as the professionals staff to carry out the job without delay.

Posted by kennygeo > 2020-12-23 16:42 | Report Abuse

if one company just operate just for covid-19 vaccine?? may be we should thank him for alert.

Posted by LOOK009 > 2020-12-23 16:58 | Report Abuse

The other counters rebounded and only this worst counter remained.

Posted by Rinshad26 > 2020-12-23 18:49 | Report Abuse

why this counter still red although vaccine news ?

Posted by Plantermen > 2020-12-23 20:03 | Report Abuse

Very disappointed

Posted by wehcant > 2020-12-23 20:05 | Report Abuse

DPHARMA need to pu$h harder.

Posted by lee9fold > 2020-12-24 00:36 | Report Abuse

So james89, your dpharma drop as well, want come out to shout again? So shall we hold or sell?

Posted by Godofgambler > 2020-12-24 01:39 | Report Abuse

Now america facing vaccine logistical distributions problem. Government need dpharma and pharma to distribute those vaccines.
I hope they wont let newbies deal the distributions.

Posted by DreamCapturer > 2020-12-24 02:53 | Report Abuse

Down 4 sen

Posted by DreamCapturer > 2020-12-24 02:54 | Report Abuse

Down 1.13%

Posted by DreamCapturer > 2020-12-24 02:54 | Report Abuse

Sikit saja la

Posted by DreamCapturer > 2020-12-24 02:54 | Report Abuse

Little bit only la

Posted by DreamCapturer > 2020-12-24 02:54 | Report Abuse

Still can tahan la

Posted by DreamCapturer > 2020-12-24 02:55 | Report Abuse

But must improve la

Posted by DreamCapturer > 2020-12-24 02:55 | Report Abuse

Good luck

Posted by Lifeunlimited > 2020-12-24 05:05 | Report Abuse

PUTRAJAYA (Dec 23): Malaysia had opted for the Covid-19 vaccine produced by United Kingdom (UK) pharmaceutical company AstraZeneca through negotiations under the COVAX facility that will ensure supply for another 10% of the country’s population.

Science, Technology and Innovation Minister Khairy Jamaluddin said this will see supply from AstraZeneca increase to 20% after an earlier procurement of 10%through direct negotiation with the company.

“AstraZeneca’s delivery of the vaccine through COVAX is being finalised but we have been told it is between March and June next year.

“Through the direct negotiation, meanwhile, (Malaysia) will receive the first shipment in April or May 2021,” he told a media conference on the development to procure Covid-19 vaccines here today.

Malaysia previously joined the COVAX facility under the ‘Optional Purchase Arrangement’ agreement which allows the government to select vaccine-manufacturing companies that participate in COVAX to obtain supplies for 10% of the country's population.

Khairy, who is also the co-chairman of the Covid-19 Vaccine Supplies Access Guarantee Special Committee (JKJAV), said the Government had also consulted with pharmaceutical company Pfizer on the option of adding another 20% vaccine supply if needed.

“The reason why (is) because in the United States only two types of vaccines have been approved, which are Pfizer and Moderna and we know it is a sure thing,” he said.

Khairy said Malaysia had previously finalised the supply agreement for 12.8 million doses of COVID-19 vaccine produced by Pfizer which is expected to arrive in the country in stages from February 2021.

On the new mutation of the COVID-19 virus in the UK, he said Pfizer was monitoring the effectiveness of its vaccine and needed six weeks to make changes if it is found to be less effective against the new strain.

Khairy said the Government was also in the final stages of negotiations with three other COVID-19 vaccine manufacturing companies, Sinovac and CanSinoBIO from China and the Gamaleya National Centre from Russia, provided those companies could add value to the country's vaccine development.

"This includes carrying out the fill-finish (bottling) process, so we buy the vaccine in bulk, bring it here and the bottling is done here. This is an important process before we have the capacity to carry out the entire vaccine development process," he said.

Khairy said the Government was also looking at companies which could forge partnerships in research and development (R&D) as well as technology transfer with local companies.

He said the Government is negotiating for access to 14 million doses of COVID-19 vaccine from Sinovac and 6.4 million doses from Gamaleya, both of which are two-dose vaccines, while the agreement with CanSinoBIO involves 3.5 million single-dose vaccines.

Overall, Khairy said all the agreements would cover 82.8% of Malaysia's population, involving a total cost of RM2.05 billion.

On Malaysia's delay in getting the COVID-19 vaccine compared with some countries such as Singapore and Canada, he said the country's financial position was not on par with other developed countries.

“No company can provide 100% supply to Malaysia because developed countries bought (the vaccines) earlier than us as they can offer more and they can make decisions because their budgets are much bigger than ours.

“Canada, for example, has bought enough vaccines to give to its people five times over. They have 500% population coverage. Our pockets are not that deep," he said.

Posted by Lifeunlimited > 2020-12-24 05:08 | Report Abuse

PUTRAJAYA (Dec 23): The Ministry of Health (MoH) is seeking to reduce the time needed to evaluate the safety and efficacy of the Covid-19 vaccine produced by US pharmaceutical giant Pfizer to less than 90 days, so a conditional approval for the drug may be granted before next March.

In normal circumstances, just the first phase of the five-phase evaluation process — which involves going through the documentation of the vaccine development process — may take between 90 and 120 days, said Health director-general Tan Sri Dr Noor Hisham Abdullah.

Evaluation of the vaccine has already started as the first scientific documents, also known as dossier, for its registration were received by the National Pharmaceutical Regulatory Agency (NPRA) on Dec 15, he said.

"So we will try our best to carry out the processes that have been identified so that we can reduce the time for us to conditionally register the vaccine within a period of less than 90 days.

"If everything is in order, maybe we will be able to conditionally approve the vaccine before March," he told reporters during the daily MoH Covid-19 press conference today.

Conditional approval with rolling submissions
A conditional approval means the vaccine will be allowed to be administered in Malaysia but with monitoring by the ministry for a period of one year, said Noor Hisham.

Pfizer will also be bound by the practice of "rolling submissions", meaning the company is required to continue submitting the latest data from its clinical trials for the NPRA to continuously review them.

"The company will have to submit their latest data for us to examine whether they are effective in cases with mutations [in the coronavirus], and whether there are complications or side effects and so on. So we will monitor adverse events following immunisation," Noor Hisham said.

By granting the conditional approval, Noor Hisham said the ministry may still override its decision, based on the latest data it reviews from the administration of the vaccine.

On Nov 24, the government, through the MoH, signed a preliminary purchasing agreement with Pfizer to obtain 12.8 million doses of its Covid-19 vaccine to meet the immunisation needs of 20% or 6.4 million Malaysians.

Under this agreement, Pfizer has pledged to deliver one million doses of its vaccine in the first quarter of 2021, 1.7 million doses in the second quarter, 5.8 million doses in the third quarter, and 4.3 million doses in the final quarter.

The Malaysian government has also inked an agreement with the United Kingdom's AstraZeneca to purchase its Covid-19 vaccine to meet the immunisation needs of 20% of the people in the country.

This is Malaysia's third agreement after the government signed with Covax to buy 10% of its vaccine needs and with Pfizer to cover 20% of Malaysia's requirements last month.

Prime Minister Tan Sri Muhyiddin Yassin has also said the government is in the final stages of negotiation with Sinovac, CanSino and Gamaleya to secure the supply of vaccines to more than 80% of the country's population.

Posted by James89 > 2020-12-24 07:58 | Report Abuse

Godofgambler Now america facing vaccine logistical distributions problem. Government need dpharma and pharma to distribute those vaccines.
I hope they wont let newbies deal the distributions

Logistics and distribution needs GDP, GSP for time- and temperature–sensitive pharmaceutical products like vaccine. You think newbies got such accreditation?

Posted by LOOK009 > 2020-12-24 09:15 | Report Abuse

疫苗灌封工作未到手 狠下200万令吉投资药剂厂房 市场快讯, 焦点讯息


Share on Facebook
Share on Twitter
发马（PHARMA，7081，主板保健股）狠下200万令吉投资尚未正式接获委任为负责新冠肺炎疫苗灌封工作的公司。

2022年就能完成设立疫苗灌封生产线；2026年就能有全新疫苗制造厂房。自2018年展开项目以来，公司目前已完成1种疫苗注册。

该局已向政府提呈计划书，包括生产容量、所需容器库存与指引等。该公司每月可生产1000万剂小瓶疫苗。公司会把位于蒲种的小针剂（SVI）厂房暂时用作疫苗灌封工作，并拨出200万令吉添购特殊疫苗灌封设备与附件，以及营运投资。

发马代理董事经理莫哈末伊克巴向媒体指出，“对我国药剂公司而言，生产容量不是问题，最大挑战反而是疫苗会是抢手货，生产商能够提供多少疫苗给大马。生产国也得优先考虑内需，才分配给其他国家。我预计疫苗应会在明年首季运到大马。”

一旦接收疫苗， 发马能立即执行灌封工作，但需要一段时间得到政府批准，交货时间大约1个月。达到大马药剂监管局（NPRA）标准后，才能正式售卖。

发马替政府运送740种药物，预计会在末季拿下另29种药物的运送工作。

发马接下来会专注扩展生产，包括新冠肺炎疫苗的灌封工作，以及落实中的全球首个清真疫苗厂房计划。

该公司跨入非处方药领域，是希望将业务版图扩大至私人领域，继续投资在药物研发，计划扩大产品组合至更多非处方药（Over-thecounter）。

他谈到，由于处方药（Ethical drugs）只能由医生开药，不像非处方药般能在药剂行购买，因此发马希望能摘下“依赖政府特许经营权”的标签，扩大成长空间。

“我们的目标不是平衡公共与私人领域的营收贡献，而是希望非特许经营权业务的营收，可以超越同行。”

另一边厢，他谨慎乐观地看待公司能在末季恢复正常表现，即政府订单回到疫情爆发前水平。尽管竞争依然激烈，但药剂行业前景仍良好。

他提到，由于市场预期发马争取疫苗灌封合约将水到渠成，发马今天再次受投资者追捧，周一股价冲破5令吉大关。

发马周一以4.52令吉开盘后节节攀升，并在午盘冲上单日最高的5.33令吉，盘中涨幅为1令吉或23%。惟该股之后回吐部份涨幅，最终以8.27令吉收市，全天大涨94仙或21.71%，是今日第2大上升股，成交量有1617万股。

Posted by lavenderguy > 2020-12-24 10:09 | Report Abuse

old news leh that one

Posted by Plantermen > 2020-12-24 11:10 | Report Abuse

Recycle news

Posted by eYuppie > 2020-12-24 15:04 | Report Abuse

EPF has been buying back lately. Will it be a good sign?

Posted by eYuppie > 2020-12-24 15:44 | Report Abuse

1) I think at around 3.50 is a good price to buy sincre EPF is accumulating back, am I right?
2) Although govt deal directly with vaccine companies overseas, the govt needs local pharmaceutical companies to handle and distribute the vaccine around the country as the govt does not have its resources to handle & distribute, am I right? Please advise.

Posted by DonWorryBeHappy > 2020-12-24 16:53 | Report Abuse

Re enter 3.49

Posted by emc2garylow > 2020-12-24 20:47 | Report Abuse

No la no la they will ask police to distribute, or postman to distribute ma

Posted by Plantermen > 2020-12-25 15:18 | Report Abuse

The last leg { fill & finish, storage & distribution } is critical

Posted by lavenderguy > 2020-12-25 23:18 | Report Abuse

if fill and finish..i can't think of others beside Duo and Pharma lo...who else in Malaysia capable?anyway, sth fishy...why keep delaying the news?

Posted by BennyWhittman > 2020-12-26 10:08 | Report Abuse

In July, 2020 PM and MOSTI announced 2 GLCs to manage Fill and Finish. Needless to say, we all know them. Pharma is not in Fill and finish yet and setting up now. Duopharma has been in fill and finish the past dozen years. So, why the holding back? They did not anticipate Vaccines from USA and UK comes already bottled.

Posted by BennyWhittman > 2020-12-26 10:12 | Report Abuse

But now that Malaysia's order is long way to go, they may consider other options, such from Russia (thru' India) or the Chinese (but still long way before approvals) GOM may now be awaiting for Russian or UK vaccines to be approved before buying bulk for fill and finish locally. Also, for long term factor, R&D by local GLCs.

Posted by BennyWhittman > 2020-12-26 10:24 |

Post removed.Why?

Posted by BennyWhittman > 2020-12-26 10:27 |

Post removed.Why?

Posted by BennyWhittman > 2020-12-26 10:28 |

Post removed.Why?

Posted by BennyWhittman > 2020-12-26 10:33 |

Post removed.Why?

Posted by Cnlim > 2020-12-26 10:49 | Report Abuse

Epf money is people money use your money then you know whether the stock is overvalue or not no point shouting undervalue or overvalue hah happy trading

Posted by BennyWhittman > 2020-12-26 10:57 |

Post removed.Why?

Posted by lee9fold > 2020-12-26 17:12 | Report Abuse

yr comment in solution thread is immature as well and it shows u didnt read the news and announcement properly. still dare to said u ace in yr business studies subject.

u must be dpharma supporter and think that only dpharma is capable of doing fill and finish for chinese vaccines?

u can support yr stock but u no need go and curse other stock.
yr dpharma also tumble down at the moment.


Posted by BennyWhittman > Dec 26, 2020 10:57 AM | Report Abuse

Does not compute. Disregard comments. Immature response.

EPF is GOM controlled Corporate and answerable to MOF with firm protocols in its investments. Not just on fanciful whims.

Posted by Plantermen > 2020-12-28 09:50 | Report Abuse

Kwsp is for long term not short term trading. PHARM is owned by Bstead { LTAT} whereas Dpharma is owned by PNB

Posted by miloo > 2020-12-28 10:28 | Report Abuse

from RM1.++ to RM3.++ still long term?

Posted by miloo > 2020-12-28 10:29 | Report Abuse

Every organisation needs $$$ now.......